Norway-based medical diagnostics company Gentian Diagnostics AS (Euronext Growth Oslo:GENT) said on Friday that its SARS-CoV-2 antibody test is moving to the next development phase.
The project has progressed from the proof-of-concept phase to the project initiation and optimisation phase. Gentian has established an official project plan with an approved budget and a dedicated project team, and the timeline to launch is set for the fourth quarter of 2021.
Gentian's SARS-CoV-2 antibody test is designed to offer the first assay on high-throughput open-access clinical chemistry platforms, supporting COVID-19 vaccination efforts and aiding in community management by the determination of immunisation status.
Viking Therapeutics plans offerings of common stock and convertible senior notes
Astellas doses first patient in Phase 3 lung cancer study
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
Ondine Biomedical deployssteriwave across five Southern Ontario hospitals
Ionis reports positive Phase 3 sefaxersen data in IgA nephropathy
X-Chem and Relay Therapeutics collaborate on Phase 3 milestone
BoomRay enters exclusive radioligand therapy asset global license agreement with Novartis
AstronauTx receives funding to explore sleep-based approaches for Parkinson's disease
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
Pharming reports positive Phase II data for leniolisib in primary immunodeficiencies
Insmed's ARIKAYCE sNDA granted priority review by FDA
Precigen announces FDA platform technology designation for AdenoVerse
Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS